Biocon Limited, a top global biopharmaceutical company listed on BSE and NSE with the ticker BIOCON, has opened its first manufacturing plant in the United States through its wholly owned subsidiary, Biocon Generics Inc. The facility is located in Cranbury, New Jersey. The event to mark its opening was attended by Phil Murphy, the Governor of New Jersey, along with Biocon’s Chairperson Kiran Mazumdar-Shaw, industry experts, partners, and customers.
Health Technology Insights: Glenmark Starts Phase 3 Trial of Envafolimab for Stage III Non-Small Cell Lung Cancer
Earlier this year, Biocon acquired the Oral Solid Dosage facility from Eywa Pharma Inc. and has since invested over 30 million dollars to upgrade it into a modern plant that can produce up to 2 billion tablets each year. Several medicines have already started being made at this site, and more are planned. This development expands Biocon’s manufacturing presence in the U.S., improves its supply chain, and helps push forward its global growth strategy.
The Cranbury plant is a big step for Biocon’s U.S. operations, helping to make important medicines more accessible, ensuring a reliable supply, and building stronger ties with healthcare providers and partners, which ultimately helps patients in America.
Health Technology Insights: Dr Batra’s Launches XOGEN Hair Regrowth Treatment in UAE
Kiran Mazumdar-Shaw, Chairperson of Biocon Group, said the FDA-approved facility in New Jersey marks a new phase in the company’s global growth. She noted that Governor Murphy’s presence at the event highlights how this facility supports innovation, creates jobs, and helps the U.S. healthcare system. She also said the plant shows Biocon’s commitment to working with healthcare professionals and communities to create a healthier and fairer future for patients worldwide.
Siddharth Mittal, CEO and Managing Director of Biocon Ltd, expressed pride in this milestone, emphasizing how it was even more special with Governor Murphy and Kiran Mazumdar-Shaw present. Mittal highlighted that this investment brings Biocon closer to American patients and healthcare providers, allowing for more efficient delivery of high-quality medicines. He said the plant strengthens supply chain resilience and supports Biocon’s mission to make affordable treatments available globally. Governor Phil Murphy welcomed Biocon’s decision to set up its first U.S. manufacturing facility in New Jersey, noting that the company has long been a trusted provider of quality medicines around the world. He said the new facility represents a major milestone for Biocon’s global expansion and shows that New Jersey continues to be a key location for medicine manufacturing globally.
Health Technology Insights: SOPHiA GENETICS, Jessa Ziekenhuis Partner on Cancer Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
